Lantheus HoldingsSTU:0L8 +1.37%87 EBITDA Margin % is 48.75% as of Mar. 2026, which is 108% above its 10-year median of 23.44. GuruFocus rates STU:0L8 with a GF Score™ of 87/100 and a GF Value™ of €79.89 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 952 Drug Manufacturers companies, Lantheus Holdings ranks better than 86.66% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Lantheus Holdings's EBITDA for the
three
months ended in Mar. 2026 was €159 Mil. Lantheus Holdings's Revenue for the
three
months ended in Mar. 2026 was €326 Mil. Therefore, Lantheus Holdings's EBITDA margin for the quarter that ended in Mar. 2026 was 48.75%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Lantheus Holdings EBITDA Margin % Related Terms
Lantheus Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Lantheus Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0L8 vs LQDA, HIMS, AMRX: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantheus Holdings EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Lantheus Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantheus Holdings (STU:0L8) has a EBITDA Margin % of 48.75% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lantheus Holdings and its competitors. This is 108% above median its historical median of 23.44. According to the industry distribution chart, Lantheus Holdings ranks #127 out of 952 companies in the Drug Manufacturers industry, placing it in the top 13.3%.
Is Lantheus Holdings' EBITDA Margin % too high?
Lantheus Holdings' current EBITDA Margin % of 48.75% is 108% above median its 10-year median of 23.44. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Lantheus Holdings' value of 48.75% is 290.9% above this industry median. Based on the distribution chart, Lantheus Holdings ranks #127 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Lantheus Holdings has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lantheus Holdings' EBITDA Margin % compare to LQDA and HIMS?
According to the Drug Manufacturers industry distribution chart, Lantheus Holdings ranks #127 out of 952 companies for EBITDA Margin %. This places Lantheus Holdings in the top 13% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.47. Lantheus Holdings' value of 48.75% is 290.9% above this benchmark. While the company's 10-year median is 23.44 vs. the industry median of 12.47, Lantheus Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lantheus Holdings's current EBITDA Margin % of 48.75% is 290.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lantheus Holdings and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lantheus Holdings's current EBITDA Margin % is 48.75%, which is 108% above median its own 10-year median of 23.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantheus Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lantheus Holdings (STU:0L8) is currently considered Modestly Overvalued. The stock's GF Value™ is €79.89, compared to a current price of €96.50 — trading 20.8% above its estimated fair value. The current EBITDA Margin % is 48.75%, which is 108% above median its 10-year median of 23.44 and 290.9% above the Drug Manufacturers industry median of 12.47. Lantheus Holdings' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Lantheus Holdings (STU:0L8), the current EBITDA Margin % is 48.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lantheus Holdings (STU:0L8) Overvalued in 2026?
Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued.
The current stock price of €96.50 is trading 20.8% above its estimated GF Value™ of €79.89.
GuruFocus considers Lantheus Holdings to be Modestly Overvalued.
Key valuation signals for STU:0L8:
EBITDA Margin %: 48.75% (108% above median its 10-year median of 23.44)
GF Value™: €79.89 vs. price of €96.50 (20.8% above fair value)
Industry Position: 290.9% above the Drug Manufacturers median (#127 of 952)
No single metric tells the full story. See the STU:0L8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
87GF Score
Get the complete analysis for STU:0L8
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0L8 has been successfully added to your 
